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It has to be kept in mind that cerebral metastases occur usual-
ly in the final stage of the metastasizing process. Therefore, in
general the survival time will be limited. Several prognostic
factors have been defined, which mainly influence the survival
time of the patients: 
– the extent of extracerebral metastases, 
– the number of cerebral lesions, 
– the time interval between the occurrence of the primary
tumor and the development of cerebral metastases, 
– the Karnofsky performance score, and 
– the age of the patient [1]. 
The indication for surgery is based on these prognostic fac-
tors. 
Surgery is indicated in patients with a solitary brain metastasis,
which means that the primary tumor is under control and the
patient is free of extracerebral metastasis. Whenever the cere-
bral lesion is accessible, surgery should be performed [2, 3]. In
these cases even long-term survivors can be expected (more
than 10 years). However, the size, the location, and the histol-
ogy of the metastasis will determine the decision pro and con-
tra surgery. 
For instance: Small-cell lung cancer is known to be very radio-
and chemosensitive. In these cases radio- or chemotherapy
will be adequate. These lesions should not be operated on,
with the exception of very big tumors, which have led to life-
threatening increase in brain pressure. Also lesions with a di-
ameter of 1 cm or less or metastases localized in the brain
stem or basal ganglia are favorably treated by radiosurgery. In
all other cases we prefer surgery whenever the patient is in
good clinical condition and under the age of 70 (up to maxi-
mally 75) years.
In singular cerebral metastasis the extent of the extracerebral
seeding, the control of the primary tumor, the Karnofsky per-
formance score, and the age of the patient will determine the
decision pro or contra operation. Stable disease, a Karnofsky
score of more than 70, and age under 70 years will favor
surgery. Numerous retrospective studies [2, 3] could demon-
Metastases to the brain occur in 20–30% of patients with sys-
temic cancer. Depending on the primary tumor the frequency
is even higher. In autopsy studies of patients with metastasiz-
ing malignant melanomas the occurrence of cerebral lesions
ranges between 40 and 75%. Most brain metastases, however,
generate from primary lung and breast carcinomas.
The brain metastasis threatens the life of the patient by in-
creasing the intracranial pressure or by seeding in functionally
important brain areas. 
Neurosurgical techniques have improved tremendously during
the last two decades. One of the main advances was the devel-
opment of neuronavigational devices. Neuronavigation is a
computer-aided method that enables us to fuse 3D-images (‘vir-
tual world’), obtained preoperatively, with the physical world of
the intraoperative situation. By this method it is possible to tar-
get deep-seated or multiple lesions by pre- and intraoperative
computed imaging and by choosing the operative approach so
as to avoid additional iatrogenic neurological deficits.
The further important progress is the intraoperative identifi-
cation of functionally important areas of the brain, e.g. the
motor cortex and the speech area by electrophysiological
monitoring, called ‘brain mapping’. Intraoperatively, the
motor cortex can be defined by somato-sensory evoked po-
tentials. The phase reversal of N20 is specific for the central
sulcus. This method can be applied on a routine basis. Brain
mapping of the speech area has to be performed on awake pa-
tients. Therefore, speech monitoring is only applied in special-
ized centers and, in general, is not necessary in patients with
metastasis.
The advances in neurosurgical techniques have led to a new
understanding in surgery of metastasis. The fact that cerebral
lesions – even small and deep-situated ones – can be ap-
proached in a reliable and safe manner, makes surgery a valu-
able alternative in metastasis treatment. 
The question arises, when is it reasonable to perform surgery
in cerebral metastases and when should other methods be pre-
ferred?
Prof. Dr. Gabriele Schackert
Klinik und Poliklinik für Neurochirurgie
Universitätsklinikum Carl Gustav Carus
Fletscherstr. 74
D-01307 Dresden (Germany)
Tel. + 49 351 458-2883, Fax -4304
Surgery of Brain Metastases – Pro and Contra
G. Schackert
Department of Neurosurgery, Technical University of Dresden
© 2002 S. Karger GmbH, Freiburg
Accessible online at: 
www.karger.com/journals/onk
Fax +49 761 4 52 07 14
E-mail Information@Karger.de
www.karger.com
strate that surgery plus radiotherapy is superior to radiothera-
py alone. In a prospective randomized trial by Patchell et al.
1990 [4] it could be shown that patients receiving surgery plus
radiotherapy lived significantly longer than those who were
treated by radiotherapy alone. The median survival time of
patients treated with radiotherapy ranges between 3 and 6
months, whereas patients treated with surgery and radiothera-
py have a median survival time of about 9–12 months. To date
it is not clear whether radiotherapy has to follow after com-
plete removal of a cerebral metastasis. In 1998, Patchell et al.
[5] published a prospective randomized trial comparing
surgery versus surgery plus radiotherapy in single brain metas-
tasis. The investigators found out that the survival time of the
patients did not differ between both groups; but they also no-
ticed that recurrent tumor growth was significantly reduced in
patients who were irradiated in addition to surgery. It has to
be demanded that patients who have undergone an operation
should be followed by early postoperative magnetic resonance
imaging (MRI), in order to determine whether complete
tumor removal could be achieved. 
The common treatment of multiple brain metastases is conven-
tional radiotherapy. Since the advances in neurosurgical tech-
niques and the establishment of radiosurgery, multiple brain
metastases can be approached by surgery or radiosurgery in
addition to radiotherapy [6]. As described above, multiple and
deep-seated lesions can be targeted by neuronavigation. Num-
ber and size of the tumors are of importance for targeted ther-
apies. It has been defined that 3 metastatic lesions with a di-
ameter of 3 cm or less can be treated by radiosurgery. Also 3
or maximally 4 lesions can be extirpated by surgery. In case of
surgery, however, the lesions may be larger than 3 cm. Espe-
cially if one of the tumors is of large size and causes elevated
brain pressure, surgical extirpation is indicated. Retrospective
studies [7–9] evaluating surgical extirpation of multiple brain
metastases could show that the median survival time of the
patients averages about 1 year and, therefore, seems to be al-
most the same as in patients with single brain metastasis.
It is always a difficult decision whether patients with multiple
lesions should be operated or not. Reasons for surgery are a
Karnofsky score of more than 70, age under 70 years, and a
stable extracranial disease. Of course, the accessibility of the
lesions is also a determining factor. Surgery should be applied
when neurological deficits can be avoided or can be dimin-
ished by extirpating the large lesion. Surgery is not indicated if
the patient has progressive disease and is in a reduced clinical
condition. In these cases it has to be considered whether ra-
diosurgery might be adequate or radiotherapy only might be
the appropriate treatment. But considering radiosurgery as
adequate treatment, the indication does not differ greatly
from that for surgery except for the size and site of the tumor,
as mentioned above [6]. 
The last question concerns the treatment of patients with re-
current brain metastases. Surgery is indicated if the time inter-
val amounts to at least 4 months, the extracerebral metastases
are stable, and the Karnofsky score is about 70. Bindal et al.
[10] could demonstrate that even after surgical extirpation of
recurrent brain metastases the median survival time may aver-
age about 11 months.
Conclusion
Surgery should be considered whenever possible. This means
that the patient has to be in good clinical condition (Karnof-
sky performance score > 70), the extracerebral metastases
should be stable, the number of cerebral lesions should not
exceed more than 3 seedings, and the age of the patient should
be below 70 years. Since brain metastases are usually well cir-
cumscribed, complete extirpation seems to be possible. Post-
operative MRI should be demanded in order to confirm com-
plete extirpation. Additional radiotherapy is indicated in case
of subtotal resection of a single lesion and in multiple lesions.
In single brain metastasis a prospective randomized trial is
necessary to prove whether conventional radiotherapy is es-
sential after surgery in the primary treatment of the tumors or
can be delayed until cerebral lesions recur. Radiosurgery is an
alternative to surgery in the treatment of metastasis.
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